Lentiviral gene therapy prevents functional deterioration in …
Nov 21, 2024 · In-Depth [prospective cohort study]: This prospective cohort study investigated the efficacy and safety of eli-cel gene therapy as a treatment for cerebral adrenoleukodystrophy. Patients were eligible if they had a confirmed diagnosis of cerebral adrenoleukodystrophy through biochemical and genetic testing, exhibited characteristic gadolinium enhancement on brain MRI, had a neurologic function ...
Finerenone reduces heart failure events in patients with HFpEF
Nov 26, 2024 · 1. In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, finerenone treatment was associated with lower rates of worsening heart failure events. 2. Finerenone treatment was not associated with an increase in serious adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Finerenone, a nonsteroidal mineralocorticoid ...
Amivantumab plus lazertinib improves survival in EGFR-mutated …
Nov 27, 2024 · 1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer (NSCLC). 2. Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutated advanced NSCLC. Evidence Rating Level: 1 (Excellent) Study Rundown ...
Paretic limbs suffer greater loss of bone mineral density following ...
Dec 4, 2024 · 1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and balance deficits Evidence Rating Level: 2 (Good) There is an increased risk of fracture due to poststroke osteoporosis. These injuries particularly affect the hip. However, current recommendations rarely recommend bone mineral density (BMD) measurements as a follow-up
Axonal injury may occur up to 9 years prior to symptom onset in ...
Dec 3, 2024 · 1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2. Until symptom onset, physical and mental well-being are comparable between affected and unaffected individuals. Evidence Rating Level: 3 (Average) Multiple sclerosis (MS) has an unclear mechanism and onset with physiological changes occurring well …
Influenza vaccination may reduce secondary infection spread …
Dec 1, 2024 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
Point of care C-reactive protein testing may be useful in guiding ...
Dec 6, 2024 · 1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations of COPD with no reduction in patient outcome Evidence Rating Level: 1 (Excellent) About 80% of patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to primary care are often given antibiotics that
Early oral anticoagulation is non-inferior to delayed treatment in ...
Dec 11, 2024 · 1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or unclassified stroke, symptomatic intracranial hemorrhage, and systemic embolism at 90 days. Evidence Rating Level: 1 (Excellent) Study Rundown: The optimal timing for starting anticoagulation in patients with acute ischemic stroke and atrial fibrillation remains unclear,
Multi-component sleep-mood group interventions may improve …
Nov 14, 2024 · 1. In this pilot randomized controlled trial, the Sleep Mood Intervention: Life Effectively (SMILE) intervention was associated with improvements in insomnia in university students. Evidence rating level: 1 (Excellent) Insomnia has a major burden on public health and can have serious long-term physical and mental health effects if left untreated.
Adjuvant durvalumab therapy improves survival in limited-stage …
Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small